Peptide record

TPDB26442

Antibacterial Anticancer Antiviral Toxicity modified_plain modified
28 source-reported length (unverified)
Basic Information
TPDB26442
Antibacterial Anticancer Antiviral Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia DRAVP 2.0
modified_plain
Yes
A modified multi-activity (Antibacterial, Anticancer, Antiviral, and other sources) peptide record curated from Peptipedia and DRAVP 2.0, without an available 3D structural model. Source-reported length: 28 (unverified).
Modified, details unspecified
Sequence
WEQKIEELLKKAEEQQKKNEEELKKLEX

Source notation is retained verbatim; residue notation and chemical identity have not been independently validated. The displayed length is source-reported and unverified.

Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
28 source-reported length (unverified)
Evidence Records 7 records
Evidence 1 Activity

Activity

50% Cytotoxicity
Toxicity
88.86±6.68 µM
Cytotoxic
50% Cytotoxicity | 88.86±6.68 | µM | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Structural and Functional Characterization of Membrane Fusion Inhibitors With Extremely Potent Activity Against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. | J Virol | 2018
Evidence 2 Activity

Activity

50% Cytotoxicity
Toxicity
114.8±12.68 µM
Cytotoxic
50% Cytotoxicity | 114.8±12.68 | µM | target cell: Human PBMC

Target

Human PBMC

Source & Reference

NA
DBAASP
Structural and Functional Characterization of Membrane Fusion Inhibitors With Extremely Potent Activity Against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. | J Virol | 2018
Evidence 3 Activity

Activity

50% Cytotoxicity
Toxicity
80.45 µM
Cytotoxic
50% Cytotoxicity | 80.45 | µM | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Monotherapy With a Low-Dose Lipopeptide HIV Fusion Inhibitor Maintains Long-Term Viral Suppression in Rhesus Macaques. | PLoS Pathog | 2019
Evidence 4 Activity

Activity

50% Cytotoxicity
Toxicity
78.52 µM
Cytotoxic
50% Cytotoxicity | 78.52 | µM | target cell: Human PBMC

Target

Human PBMC

Source & Reference

NA
DBAASP
Monotherapy With a Low-Dose Lipopeptide HIV Fusion Inhibitor Maintains Long-Term Viral Suppression in Rhesus Macaques. | PLoS Pathog | 2019
Evidence 5 Activity

Activity

50% Cytotoxicity
Toxicity
72.23 µM
Cytotoxic
50% Cytotoxicity | 72.23 | µM | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Monotherapy With a Low-Dose Lipopeptide HIV Fusion Inhibitor Maintains Long-Term Viral Suppression in Rhesus Macaques. | PLoS Pathog | 2019
Evidence 6 Activity

Activity

50% Cytotoxicity
Toxicity
37.37 µM
Cytotoxic
50% Cytotoxicity | 37.37 | µM | target cell: Human PBMC

Target

Human PBMC

Source & Reference

NA
DBAASP
Monotherapy With a Low-Dose Lipopeptide HIV Fusion Inhibitor Maintains Long-Term Viral Suppression in Rhesus Macaques. | PLoS Pathog | 2019
Evidence 7 Activity

Activity

Toxicity
Cytotoxic
Cytotoxicity: [Ref.30089693]TZM-bl cell:CC50=112.9 ± 2.21 µM ##MT-4 cell:CC50=94.06± 4.97 µM ##HEK293T cell:CC50=88.86± 6.68µM ##PBMC:CC50=114.8± 12.68 µM.

Source & Reference

NA
DRAMP
J Virol. 2018 Sep 26 92(20):e01088-18.